Purpose This article aims to analyse the key regulatory guidelines across the globe
concerning biosimilars. Materials and methods Review of the current literature. Results …

Many key biologics are scheduled to lose their patent by the year 2020, which will provide
the opportunity to other biopharmaceutical companies to develop the similar biologics …

Objective: The aim was to critically evaluate well-established regulatory agencies mAb
biosimilar guidelines for development and marketing authorization about quality, efficacy …

Epitomizing one of the rapidly maturing segments of pharmaceutical industry, biologics
gestalt has severely implicated treatment algorithms of many life-threatening diseases …

Financial constraints faced by the families play a vital role in cancer treatment refusal, non-
adherence, and failure of the prescribed therapy. This review aims to give an insight into the …

Pharmaceutical industry in India has made significant positive impact to health care
outcomes in India and other developing as well as developed countries. Indian pharma …

The steep rise in the cost of brand name biologics and expiration of their patents led to the
arrival of several new biosimilars in the United States (US) and European Union (EU) …

Developing new biologics has led to regulations and norms aimed at guaranteeing their
safety, quality and effectiveness, in terms of marketing, prescription, use, interchangeability …

Biosimilars are biological medications that closely resemble FDA-approved biological
medications in terms of structure as well as functions and are approved according to the …

Retinal disease management has witnessed remarkable advances with the development of
anti-VEGF molecules such as Lucentis®(ranibizumab), Eylea®(aflibercept), off-label …